Enteric‐coated cysteamine for the treatment of paediatric non‐alcoholic fatty liver disease

Aliment Pharmacol Ther 2011; 33: 1036–1044

[1]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[2]  J. Gangoiti,et al.  Long-term treatment of cystinosis in children with twice-daily cysteamine. , 2010, Jornal de Pediatria.

[3]  T. Funahashi,et al.  Visceral Obesity and Hypoadiponectinemia are Significant Determinants of Hepatic Dysfunction: An Epidemiologic Study of 3827 Japanese Subjects , 2009, Journal of clinical gastroenterology.

[4]  A. Feldstein,et al.  Cytokeratin‐18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study , 2009, Hepatology.

[5]  N. Hayashi,et al.  Adipocytokines and liver disease , 2008, Journal of Gastroenterology.

[6]  P. Maher,et al.  A novel approach to enhancing cellular glutathione levels , 2008, Journal of neurochemistry.

[7]  C. Winterbourn,et al.  Thiol chemistry and specificity in redox signaling. , 2008, Free radical biology & medicine.

[8]  C. Sirlin,et al.  Review article: epidemiology, pathogenesis and potential treatments of paediatric non‐alcoholic fatty liver disease , 2008, Alimentary pharmacology & therapeutics.

[9]  M. Wajner,et al.  Antioxidant Effect of Cysteamine in Brain Cortex of Young Rats , 2008, Neurochemical Research.

[10]  M. Wajner,et al.  Effects of cysteamine on oxidative status in cerebral cortex of rats , 2008, Metabolic Brain Disease.

[11]  P. Wood,et al.  Cellular thiol pools are responsible for sequestration of cytotoxic reactive aldehydes: Central role of free cysteine and cysteamine , 2007, Brain Research.

[12]  A. Saltiel,et al.  Obesity induces a phenotypic switch in adipose tissue macrophage polarization. , 2007, The Journal of clinical investigation.

[13]  Jeanne M Clark,et al.  Weight Loss as a Treatment for Nonalcoholic Fatty Liver Disease , 2006, Journal of clinical gastroenterology.

[14]  C. Nievergelt,et al.  Histopathology of pediatric nonalcoholic fatty liver disease , 2005, Hepatology.

[15]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[16]  E. Çakır,et al.  Systemic Markers of Lipid Peroxidation and Antioxidants in Patients with Nonalcoholic Fatty Liver Disease , 2005, The American Journal of Gastroenterology.

[17]  Arthur J. L. Cooper,et al.  Mechanism for the inhibition of transglutaminase 2 by cystamine. , 2005, Biochemical pharmacology.

[18]  Guoyao Wu,et al.  Glutathione metabolism and its implications for health. , 2004, The Journal of nutrition.

[19]  R. Deutsch,et al.  Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. , 2003, The Journal of pediatrics.

[20]  R. Deutsch,et al.  The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine. , 2003, The Journal of pediatrics.

[21]  S. Uchida,et al.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.

[22]  R. Karim,et al.  NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome , 2002, Hepatology.

[23]  J. Clore,et al.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.

[24]  J. Lavine.  Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. , 2000, The Journal of pediatrics.

[25]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[26]  L. Lorand.  DRPLA aggregation and transglutaminase, revisited , 1998, Nature Genetics.

[27]  M. Zern,et al.  A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kappaB. , 1997, The American journal of physiology.

[28]  H. Kataoka,et al.  Determination of cysteamine and cystamine by gas chromatography with flame photometric detection. , 1993, Journal of pharmaceutical and biomedical analysis.

[29]  W. Gahl,et al.  Cystine transport is defective in isolated leukocyte lysosomes from patients with cystinosis. , 1982, Science.

[30]  E. Sellers,et al.  Treatment of acetaminophen poisoning. , 1981, Canadian Medical Association journal.

[31]  A. Proudfoot,et al.  Cysteamine or N-acetylcysteine for paracetamol poisoning? , 1978, British medical journal.

[32]  Bruce A Barshop,et al.  Twice-daily cysteamine bitartrate therapy for children with cystinosis. , 2010, The Journal of pediatrics.

[33]  R. Liu,et al.  Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis. , 2010, Free radical biology & medicine.

[34]  A. Sanyal.  Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease , 2005, Nature Clinical Practice Gastroenterology &Hepatology.